Fully automatic aseptic liquid filling system - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fully automatic aseptic liquid filling system


The FPC50W is a flexible aseptic filling system with integrated full or partial stoppering and crimp capping of vials. The system can deliver fill volumes ranging from 0.1ml to 100ml and a filling accuracy of ± 0.5% which is check-weighed throughout the filling batch, with adjustments made automatically if required.

The FPC50W is ideally suited to applications involving small batches such as contract fillers and research and development trials where cross contamination must be avoided. For example, the use of Flexicon's asepticsu sterile, disposable tubing, filling needles and fluid bags, ensures minimal human contact with the filling operation. In addition, the entire single-use fluid path is contained, making cleaning and validation extremely simple.

As well as check-weighing 100% of the vials filled, the FPC50W also permits fast change-over between batches of liquids to be filled. This helps to eliminate time consuming and costly logistic procedures related to having dedicated pumps in stock.

Peristaltic pumps are ideally suited to filling applications: they provide superior flow rate stability and metering accuracy; facilitate aseptic and sterile processes; have extensive chemical compatibility; and are inherently hygienic and safe to run.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here